drugset
drugset / Trial / NCT00685815

Intravenous Iron Metabolism in Restless Legs Syndrome

NCT00685815 ↗

Phase 2 Completed 12 enrolled American Regent, Inc. National Institute on Aging (NIA) · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome

Timeline

Start
2006-11
Primary completion
2010-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 500 mg Intravenous

Indications

restless legs syndrome